Factors influencing serum concentration of zonisamide in epileptic patients. 1992

M Kimura, and N Tanaka, and Y Kimura, and K Miyake, and T Kitaura, and H Fukuchi, and Y Harada
Department of Pharmaceutical Services, Hiroshima University Hospital, Japan.

The relationship between daily dose and serum concentration of zonisamide (ZNS) and the effects of patient age on the serum level/dose (L/D) ratio for ZNS were studied in epileptic patients (mean age +/- S.D. = 10.6 +/- 6.2 years) who chronically received ZNS. The influence of phenytoin (PHT), phenobarbital (PB), carbamazepine (CBZ) and valproic acid (VPA) on the serum protein binding of ZNS in vitro and the correlation between total and unbound serum levels of ZNS in patients were also examined. Significant correlations were obtained between daily dose per body weight or per body surface area and serum level of ZNS. The correlation coefficient of the latter was higher than that of the former. There was no effect of age on the L/D ratio on the basis of body surface area, whereas that on the basis of body weight increased significantly with age. No significant increase in the free fraction of ZNS was observed in the presence of PHT, PB and CBZ except VPA in vitro. There were significant correlations between total and unbound serum levels of ZNS in the two patient groups coadministered with and without VPA. Although the free fraction of ZNS in the former was significantly higher than that of the latter, the increase was small. These results suggest that dosage regimens on the basis of body surface area would be more accurate than those on a body weight basis and that there is little effect of other antiepileptics on the serum protein binding of ZNS.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D007555 Isoxazoles Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions. Isoxazole
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D004827 Epilepsy A disorder characterized by recurrent episodes of paroxysmal brain dysfunction due to a sudden, disorderly, and excessive neuronal discharge. Epilepsy classification systems are generally based upon: (1) clinical features of the seizure episodes (e.g., motor seizure), (2) etiology (e.g., post-traumatic), (3) anatomic site of seizure origin (e.g., frontal lobe seizure), (4) tendency to spread to other structures in the brain, and (5) temporal patterns (e.g., nocturnal epilepsy). (From Adams et al., Principles of Neurology, 6th ed, p313) Aura,Awakening Epilepsy,Seizure Disorder,Epilepsy, Cryptogenic,Auras,Cryptogenic Epilepsies,Cryptogenic Epilepsy,Epilepsies,Epilepsies, Cryptogenic,Epilepsy, Awakening,Seizure Disorders
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000078305 Zonisamide A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization. 3-Sulfamoylmethyl-1,2-benzisoxazole,AD 810,AD-810,CI 912,CI-912,Zonegran,Zonisamide Monosodium,3 Sulfamoylmethyl 1,2 benzisoxazole,AD810,CI912
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths

Related Publications

M Kimura, and N Tanaka, and Y Kimura, and K Miyake, and T Kitaura, and H Fukuchi, and Y Harada
October 1977, British journal of clinical pharmacology,
M Kimura, and N Tanaka, and Y Kimura, and K Miyake, and T Kitaura, and H Fukuchi, and Y Harada
May 1993, No to hattatsu = Brain and development,
M Kimura, and N Tanaka, and Y Kimura, and K Miyake, and T Kitaura, and H Fukuchi, and Y Harada
May 1982, Der Nervenarzt,
M Kimura, and N Tanaka, and Y Kimura, and K Miyake, and T Kitaura, and H Fukuchi, and Y Harada
April 1973, Neurology,
M Kimura, and N Tanaka, and Y Kimura, and K Miyake, and T Kitaura, and H Fukuchi, and Y Harada
April 1976, Fortschritte der Medizin,
M Kimura, and N Tanaka, and Y Kimura, and K Miyake, and T Kitaura, and H Fukuchi, and Y Harada
January 1974, Medical instrumentation,
M Kimura, and N Tanaka, and Y Kimura, and K Miyake, and T Kitaura, and H Fukuchi, and Y Harada
August 2023, BMC psychiatry,
M Kimura, and N Tanaka, and Y Kimura, and K Miyake, and T Kitaura, and H Fukuchi, and Y Harada
February 1964, Ugeskrift for laeger,
M Kimura, and N Tanaka, and Y Kimura, and K Miyake, and T Kitaura, and H Fukuchi, and Y Harada
April 1987, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde,
M Kimura, and N Tanaka, and Y Kimura, and K Miyake, and T Kitaura, and H Fukuchi, and Y Harada
August 1998, Clinical nephrology,
Copied contents to your clipboard!